Cetirizine ophthalmic - Nicox

Drug Profile

Cetirizine ophthalmic - Nicox

Alternative Names: AC-170; cetirizine ophthalmic solution, 0.24% - Nicox; ZERVIATE

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aciex Therapeutics
  • Developer NicOx
  • Class Acetic acids; Antiallergics; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Allergic conjunctivitis

Most Recent Events

  • 21 Sep 2017 Cetirizine ophthalmic - Nicox market licensed to Eyevance Pharmaceuticals in USA
  • 31 May 2017 Registered for Allergic conjunctivitis in USA (Ophthalmic) (First global approval)
  • 11 Apr 2017 FDA assigns PDUFA action date of (08/09/2017) for cetirizine ophthalmic for Allergic conjunctivitis (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top